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Ferritin levelAbstract Introduction: Early detection of lung cancer is vital to improve lung cancer survival rates
and also could change the disease outcome. There is increasing interest in EBC analysis, because the
method of collection is simple, non invasive, repeatable and does not necessarily require patient
cooperation. This study aimed at estimating ferritin in exhaled breath condensate (EBC) in an
attempt to evaluate its role as a non invasive marker for early detection of lung cancer.
Patients and methods: This study included 40 patients diagnosed as lung cancer as well as 20
patients with chronic obstructive pulmonary disease (COPD) and 20 control subjects. Ferritin level
was estimated in EBC of all included subjects.
Results: The ferritin level in EBC was the highest in the lung cancer group of patients (>60
ng/ml) in comparison to COPD patients (35–40 ng/ml). The ferritin level was the lowest in the
control group. The statistical comparison of the ferritin level among the 3 groups was highly signiﬁ-
cant (p< 0.001).
Conclusion: The estimated ferritin level in EBC can serve as a non invasive and inexpensive
marker for screening of lung cancer.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Introduction
Lung cancer is the leading cause of cancer related mortality in
the world. The American Cancer Society estimated that in
2013 the disease accounts for almost 159,500 deaths in the
United States or approximately 27% of all cancer deaths in
the country. Lung cancer accounts for about 14% and 12%of all new cancer diagnoses in males and females, respectively,
and nearly 70% of patients with lung cancer present with
locally advanced or metastatic disease at initial diagnosis [1].
Lung cancer is a highly prevalent malignancy that is
associated with substantial morbidity and mortality.
Histologically, it is divided into non-small cell lung cancer
(NSCLC), the more common form, and small cell carcinoma.
Approximately 85% of lung tumors are NSCLC, which
comprises three major histological subtypes: adenocarcinoma,
squamous cell carcinoma and large-cell carcinoma [2].
Initiation and progression of lung carcinoma are the result
of the interaction between genetic and environmental factors.
Table 1 Demographic data and its comparison among the 3 studied groups.
NSLC group no.: 40 COPD group no.: 20 Control group no.: 20 X2 P
Age groups
<50 4 (10%) 3 (15%) 20 (100%) 52 <0.001
>50 36 (90%) 17 (85%) 0
Sex
Female 5 (12.5%) 0 13 (65%) 28 <0.001
Male 35 (87.5%) 20 (100%) 7 (35%)
Smoker 35 (87.5%) 20 (100%) 2 (10%) 49 <0.001
Non smoker 5 (12.5%) 0 18 (90%)
Table 2 Distribution of histopathology in the NSCLC group.
Variables No %
Squamous cell carcinoma 22 55
Adenocarcinoma 18 45
466 S.S. Ashmawi et al.Epidemiological studies indicate that cigarette smoking has a
strong association, since approximately 80–90% of lung
cancers are attributable to cigarette smoking [3].
Early detection of lung carcinoma could change the disease
outcome; the survival rate can increase dramatically. In the
effort to improve early detection, many imaging and cytology
based strategies have been employed [4].
Recent attention has focused on EBC as a non invasive
method for studying the composition of airway lining ﬂuid;
it contains aerosol particles in which several non volatile com-
pounds have been identiﬁed. EBC analysis of inﬂammatory
biomarkers; (that might reﬂect different aspects of lung inﬂam-
mation or oxidative stress, which is an important component
of inﬂammation) is a non invasive method which has the
potential to be useful for monitoring airway inﬂammation in
patients with respiratory diseases [5].
An interesting inﬂammatory marker studied recently in
lung cancer is ferritin. Ferritin an iron-storing protein, was
initially measured in the serum of patients affected by lung
cancer and found to have increased. Elevated levels of ferritin
in the serum of patients with non small cell lung cancer
(NSCLC) were attributed to an inﬂammation rather than to
body iron overload. Ferritin was also measured in samples
from airways such as bronchoalveolar lavage (BAL) and
bronchial secretion. The source of ferritin in airways is
postulated as stemming from the transudation of serum iron
into airways [6].
This study aimed at estimating ferritin level in exhaled
breath condensate (EBC) in an attempt to evaluate its role
as a non invasive marker for early detection of lung cancer.
Patients and methods
The present study was conducted at the Chest Department of
Ain Shams University Hospitals in the period between June
2013 and January 2014. This study included a total of 80
subjects subdivided into 3 groups; Group (A) consists of forty
patients diagnosed as NSCLC, Group (B) consists of twenty
patients with COPD diagnosed according to the recent
guidelines [7], and Group (C) consists of twenty healthy
subjects recruited from the Ain Shams University hospitals
and served as controls.
All the included subjects underwent detailed medical his-
tory taking, thorough clinical examination, routine laboratory
investigations, plain chest X-ray postero-anterior view, and
computed tomography (CT) scan of the chest.Exhaled breath condensate collection and processing
Samples of EBC were collected as a liquid during oral tidal
breathing in the seated position for 10 min using the
EcoScreen (Jaeger, Hoechberg, Germany). Subjects did not
wear nose clips and reported that they had ingested no liquids
or solids in the previous 2 h. Sample collection was performed
according to the American Thoracic Society/European
Respiratory Society Task Force (ATS/ERS Task Force)
guidelines [8].
Statistical analysis
Statistical analyses were performed utilizing statistical
software (SPSS for Windows, version 20.0; SPSS Inc,
Chicago, IL). Descriptive statistics was presented as either
mean ± standard deviation (SD) or number and percentage.
Differences in measures between groups were assessed using
the independent-sample t test for parametric data, and
Mann–Whitney–Wilcoxon U test for non-parametric data.
Statistical correlation was done using Pearson’s correlation
coefﬁcient test. Receiver operator characteristic curve (ROC
curve) was used to ﬁnd out the best cut off value, and validity
of certain variable. Statistical signiﬁcance was set at p< 0.05.
Results
Eighty subjects participated in this study, sixty of them were
admitted at the Chest Department of Ain Shams University
Hospitals and the remaining twenty healthy subjects served
as controls and were recruited from the pulmonary function
unit of the Chest Department of Ain Shams University
Hospitals. The demographic data as well as its comparison
among the 3 studied groups is shown in Table 1. There was
a highly signiﬁcant statistical difference as regards age, sex,
and smoking status.
Table 3 Comparison between the studied groups as regards ferritin level.
Ferritin level (ng/ml) NSCLC group
n= 40
COPD group
n= 20
Controls group
n= 20
x2 P
20–25 0 0 20 (100%) 160 <0.001
35–40 0 20 (100%) 0
>60 40 (100%) 0 0
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Figure 1 Ferritin level between the studied groups.
Table 4 Validity of ferritin level in the prediction of lung
cancer.
Variables %
Best cut oﬀ 40
Area under the curve (AUC) 1.00
Sensitivity 100
Speciﬁcity 100
PPV 100
NPV 100
Accuracy 100
Figure 2 ROC curve.
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carcinoma, while 45% were diagnosed as adenocarcinoma
(Table 2).
The comparison between the studied groups as regards
ferritin level showed that 100% of the studied NSCLC group
had higher ferritin above 60, while in the COPD group the
level was 35–40, and in controls the level was 20–25 with a
highly signiﬁcant statistical difference between groups
(Table 3 and Fig. 1).
The ferritin level was found to be a highly valid predictor of
lung cancer at a cut-off of 40 ng/ml with a very high sensitivity
and speciﬁcity (Table 4 and Fig. 2).
Discussion
Lung cancer has been the most common cancer diagnosed
each year since 1985. Lung cancer had a higher incidence
among males worldwide than any other cancer, followed by
prostate cancer and stomach cancer. Among females, lung
cancer was the fourth most diagnosed cancer, behind breast
cancer, cervical cancer and colorectal cancer [9].
Aberle et al. [10] stated that the aim of lung cancer screen-
ing is to reduce lung cancer-related mortality by detecting
more patients in earlier potentially curable stages. It was found
in historical randomized controlled trials on the use of periodi-
cal chest X-ray and/or sputum cytology were negative, and
screening based on these techniques is therefore not recom-
mended. Low-dose computed tomography more sensitive for
the detection of small nodules was studied in more recent
randomized controlled trials (RCTs).
Reinhold et al. [11] found that there is increasing interest in
EBC analysis, because the method of collection is simple, non
invasive, repeatable and does not necessarily require patient
cooperation only spontaneous breathing through either nose
or mouth. The future of EBC is an immediate or in time detec-
tion of speciﬁc biomarkers to assess the presence and/or the
severity of respiratory or non respiratory diseases to evaluate
reactive responses of the respiratory system to exogenous toxic
substances, or to assist therapeutic interventions.
Stites et al. [12] mentioned that the source of ferritin in
airways in conditions such as inﬂammation is postulated as
stemming from the transudation of serum iron into airways.
Ferritin was proved to be measurable and present in high con-
centrations in EBC of lung diseases such as asthma and cystic
ﬁbrosis, it seldom has been studied in EBC of patients with
lung cancer [13].
This study revealed that majority of NSCLC patients were
males above 50 years and this is consistent with Giovanna
et al. [14]. As for the COPD group of patients; all were male
smokers, possibly because smoking is more common in males
as well as being the most common predisposing factor for
COPD. Moreover, most of NSCLC patients were smokers
(87.5%) and this agreed with Giovanna et al. [14].
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squamous cell carcinoma (55%) and 45% were adenocarci-
noma and this matches with the study of Giovanna et al.
[14] as they had the same results.
Results of our study showed that ferritin level in EBC of
group A (NSCLC) is above 60 ng/ml and 35–40 in group B
(COPD) and 20–25 in group C (control) with higher sensitivity
(100%) and speciﬁcity (100%) with PPV = 100%, NPV =
100% and accuracy 100%, which represent a highly sta-
tistically signiﬁcant difference between the studied groups
and this is in consistent with Giovanna et al. [14] who revealed
a signiﬁcant statistical difference as regards the ferritin level
between their two studied groups (control and NSCLC).
Finally, it is worth mentioning that this study has some lim-
itations; ﬁrst: the estimation of ferritin level in EBC in patients
with other types of NSLC and SCLC was not performed.
Second: the lack of the de-aeration step in EBC sampling
insures the stability of the EBC values.
In conclusion, estimating ferritin level in EBC is a non
invasive and inexpensive method for screening of lung cancer
with sensitivity and speciﬁcity and can therefore be applied
widely in Chest hospitals. Future studies should implement
EBC ferritin in combination with serum ferritin and ferritin
level in pleural effusion to be used as a panel for early detec-
tion of lung cancer.
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